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Background.Thepharmacokinetics ofmany medications change as we age, thusmost would assumedosingstrategies would adjust
for these changes. The objective of this study is to evaluate the initial vancomycin dosing in three pediatric age groups based on
measured serum trough concentrations. Methodology. This retrospective database review included patients aged from 1 month to
18years old admitted to the Moses H. Cone Memorial Hospital. Patients had to have received vancomycin dosed at 15mg/kg
every 8hours with an appropriately measured trough concentration. The primary outcome was to determine the percentage
of patients in 3 pediatric age groups achieving therapeutic trough concentrations with the initial vancomycin dosing regimen.
Results. Twenty-ﬁve patients were included in the study. None of the patients had therapeutic trough concentrations after receiving
vancomycin 15mg/kg every 8hours. Only one patient had a supratherapeutic level, while all of the other patients had levels less
than 10mcg/mL. Conclusions. Vancomycin 15mg/kg every 8hours did not provide therapeutic serum trough concentrations for
anypediatricagegroups.Higherdosesand/ormorefrequentdosingregimensneedtobeevaluatedforeachagegrouptodetermine
the most appropriate strategies for producing therapeutic trough concentrations.
1.Introduction
The pharmacokinetics of many medications change as we
age, dictating the need for dosing strategies that adjust for
these changes. One such example is vancomycin. The half-
life of vancomycin ranges from approximately 2 to 10 hours
depending on age (Table 1)[ 1]. Focusing on patients aged
3 months to 4 years old compared to those older than 4
years, there is an approximately twofold diﬀerence in their
half-lives, which can lead to a huge diﬀerence in the dosing
strategies of vancomycin.
With these age-related diﬀerences in pharmacokinetics,
one would expect dosing strategies to be adjusted. However,
dosing of vancomycin in the pediatric population, excluding
neonates, is not age-speciﬁc (i.e., infants, children, and
adolescents), failing to adjust for the variability in pharma-
cokinetics among pediatric age groups (Table 2)[ 1, 2].
Previous studies have shown that higher doses and
more frequent dosing strategies are needed to produce
therapeutic concentrations. Glover and colleagues evaluated
the dosing of vancomycin in 76 pediatric intensive care unit
(PICU) patients aged from 1 month to 18 years old [3].
Vancomycin 20mg/kg given every 8 hours was needed to
obtain therapeutic concentrations. In another retrospective
database review, Benner and colleagues evaluated several
vancomycin dosing schemes in 357 patients aged from 1
m o n t ht o1 8y e a r so l d[ 4]. Vancomycin 10mg/kg every 6 to
8hours was compared to vancomycin 15 to 20mg/kg every
6 to 8hours. The latter dosing strategies were needed to
produce more therapeutic levels.
At the Moses H. Cone Memorial Hospital, the standard
pediatric dosing protocol ordered by the physicians for
vancomycin is 15mg/kg every 8hours. The objective of this
study is to assess the need for a revision to this initial
vancomycin dosing strategy in three pediatric age groups.
To our knowledge, there are not any other studies available
that have evaluated vancomycin dosing strategies based on
diﬀerent pediatric age groups. We hypothesize that patients
falling into the infant and adolescent age groups would
potentially still reach goal serum trough levels, while those in2 International Journal of Pediatrics
Table 1: Vancomycin half-life [1].
Age group Half-life
Neonates 6–10 hours
3 months to 4 years old 4 hours
>4 years old 2.2–3 hours
Adolescents Not well deﬁned (hypothesized to be
similar to an infant)
Adults 5–8 hours
Table 2: Vancomycin dosing regimens [1, 2].
Age group Dosing Regimen
Neonates 10–15 mg/kg every 6–18 hours
depending on PMA and PNA
Infants, children, and
adolescents
10 mg/kg every 6 hours (traditional
dosing) or 15–20 mg/kg every 6–8
hours (serious infection)
Adults 15–20 mg/kg every 8–12 hours
Moses H. Cone
Hospital (pediatrics) 15 mg/kg every 8 hours
PMA: postmenstrual age; PNA: postnatal age.
the child age group would need higher starting doses and/or
more frequent dosing regimens.
2.MaterialsandMethods
This retrospective study reviewed data from patients admit-
ted to the Moses H. Cone Memorial Hospital general
pediatric unit and PICU between 2006 and 2010. Patients
were included if the ages were from 1 month to 18 years
old, received vancomycin 15mg/kg every 8hours, and had
a respective trough concentration measured appropriately,
deﬁned as a serum level drawn approximately 30minutes
before the third or subsequent doses. Patients were excluded
if they had poor renal function, deﬁned as an increase in
serum creatinine by 50 percent or more from their baseline
or normal serum creatinine for their age. Neonates were also
excluded from the study.
Electronic medical records were reviewed, and data
collected include the initial vancomycin dose and respective
serum trough concentration, timing of the trough concen-
tration, patient demographics, and renal function.
The primary outcome was the percentage of patients
achieving goal serum trough concentrations deﬁned as 10 to
15mcg/mLforcellulitisand15to20mcg/mLforbacteremia,
pneumonia, meningitis, osteomyelitis, and endocarditis.
Secondaryoutcomesincludedthepercentageofpatientswith
subtherapeutic and supratherapeutic trough concentrations
aswellastheindicationofvancomycin.Patientsweredivided
into three groups based on their age for analysis. Infants
were deﬁned as ages from 1 to 23 months old, children from
2 to 12 years old, and adolescents from 13 to 18 years old
[5]. Demographics and the primary outcome were analyzed
using descriptive statistics, while the secondary outcomes
were analyzed by the Fisher’s exact test. The study was
approved by the Institutional Review Board of the Moses
Cone Health System.
3. Results
Of the 50 patients’ medical records reviewed, only 25
were included in the analysis due to exclusions. Eighteen
patients had been started on vancomycin using diﬀerent
dosing strategies other than 15mg/kg every 8hours. Four
patients were excluded due to inappropriate trough timing,
in which the trough concentration was charted as being
measured after the next dose of vancomycin. Other patients
who were excluded consist of one patient being less than
one month old, one had no weight documented, and
three had documented acute renal failure, of which 2 were
appropriately started on a diﬀerent dosing regimen.
Baseline demographics of the three patient groups were
similar. The majority of patients were female and Caucasian
in the infant and child age groups, while all the patients
in the adolescent group were male and evenly divided
between Caucasians and African Americans (Table 3). None
of the patients in the cohort had cystic ﬁbrosis or any past
medical histories that could have increased their volume
of distribution. Most of the patients had their trough
concentrations collected with the third or fourth doses of
vancomycin and were on vancomycin for less than one week.
In regards to the primary outcome, none of the patients
achievedgoalserumtroughconcentrationswithvancomycin
dosed at 15mg/kg every 8hours (Table 4). The majority of
the trough concentrations were subtherapeutic, with only
one infant having a supratherapeutic level (Table 5). This
patient was also on potentially nephrotoxic agents, including
gentamicin and furosemide.
The serum trough concentrations of the infants were
more likely to fall between 5 to 10mcg/mL (55.6% in
the infant group compared to 41.7% in the child age
group, P = 0.86), while those in the child age group
had more levels less than 5mcg/mL (41.7% in the infant
group compared to 58.3% in the child age group, P =
0.86) (Table 6). The primary indication of vancomycin was
cellulitis (Table 7). Other indications of vancomycin were
pneumonia, meningitis, and bacteremia.
4. Discussion
Vancomycin is an antimicrobial indicated in patients suﬀer-
ing from infections with methicillin-resistant Gram-positive
pathogens [1]. It is usually used as the empiric therapy
if the proportion of methicillin-resistant Gram-positive
pathogens is signiﬁcant (>5%) in the patient population,
or if the patients are suspected to be suﬀering from serious
infections (e.g., bacteremia), or if other antimicrobials
like clindamycin cannot eﬀectively combat the infection
believed to be caused by methicillin-resistant Gram-positive
pathogens. At our institution, vancomycin is only utilized
when the latter two incidences occur. Our drug of choice
for less serious infections with methicillin-resistant Gram-
positive pathogens is clindamycin, since such pathogens haveInternational Journal of Pediatrics 3
Table 3: Demographics.
Parameters Infant
(N = 9)
Child
(N = 12)
Adolescent
(N = 4)
Room, No. (%)
General Pediatric 6 (66.7) 12 (100) 4 (100)
PICU 3 (33.3) — —
Gender, No. (%)
Male 4 (44.4) 5 (41.7) 4 (100)
Race, No. (%)
Caucasian 4 (44.4) 7 (58.3) 2 (50)
African American 3 (33.3) 4 (33.3) 2 (50)
Hispanic 2 (22.2) — —
Asian — 1 (8.3) —
Mean age, yrs (range) 0.78
(1–23 months)
5.3
(2–12)
14.8
(13–17)
Mean initial creatinine
level, mg/dL (range)
0.4
(0.3–0.5)
0. 4
(0.3–0.7)
0.6
(0.3–0.8)
Timing of level, No. (%)
Before 3rd dose 4 (44.4) 6 (50) 3 (75)
Before 4th dose 3 (33.3) 5 (41.7) —
Before >4th dose 2 (22.2) 1 (8.3) 1 (25)
Mean duration of
therapy, days (range) 4.9 (1–21) 3.8 (1–16) 2.5 (1–4)
Table 4: Percentage of patients achieving goal vancomycin serum
trough concentrations.
Age group Patients, no. %
Infant 9 0
Child 12 0
Adolescent 4 0
Table 5: Vancomycin trough concentrations.
Age group Subtherapeutic, no. (%) Supratherapeutic, no. (%)
Infant 8 (88.9) 1 (11.1)
Child 12 (100) —
Adolescent 4 (100) —
P = 0.52.
Table 6: Distribution of subtherapeutic vancomycin trough con-
centrations.
Age group
Trough concentrations (mcg/mL), no. (%)
<5 5–10 10–15
Infant 3 (33.3) 5 (55.6) —
Child 7 (58.3) 5 (41.7) —
Adolescent 2 (50) 2 (50) —
P = 0.86.
a sensitivity of approximately 95% to clindamycin in our
pediatric population.
Many previous studies targeted vancomycin trough
concentrations ranging from 5 to 15mcg/mL, which is
lower than the new recommendations by the American
Table 7: Indications of vancomycin.
Indication Infant, no.
(%)
Child, no.
(%)
Adolescent,
no. (%)
Cellulitis 4 (44.4) 5 (41.7) 2 (50)
Pneumonia 2 (22.2) 6 (50) 2 (50)
Meningitis 2 (22.2) — —
Bacteremia 1 (11.1) 1 (8.3) —
P = 0.66.
SocietyofHealthSystemPharmacists,theInfectiousDiseases
Society of America, and the Society of Infectious Disease
Pharmacists [6]. Due to the rise in the mean inhibitory
concentration (MIC), it is recommended that vancomycin
trough concentrations should be maintained at least above
10mcg/mL for less severe infection like cellulitis and
between 15 and 20mcg/mL for more complicated infections
like bacteremia, pneumonia, meningitis, osteomyelitis, and
endocarditis. These recommendations are primarily for the
adult population, but they can probably be extrapolated to
pediatric patients.
Our institution’s standard physician vancomycin dosing
protocol of 15 mg/kg every 8 hours did not achieve the new
goalserumtroughconcentrationsforanyofthepediatricage
groups.Onlyonepatienthadalevelgreaterthan10mcg/mL,
and the level was found to be supratherapeutic. Again, this
patientwasalsoonotheragentslikelytocausenephrotoxicity
including furosemide and gentamicin. Previous studies have
shown that the risk of nephrotoxicity while on vancomycin
increases with concomitant use of other nephrotoxic agents
like gentamicin, as well as an extended duration of therapy,
leading to high concentrations of vancomycin and potential
kidney damage [7].
In a study by Glover and colleagues, vancomycin
20mg/kg every 8hours produced a mean trough concen-
tration of 7.8mcg/mL, whereas vancomycin 15 to 20mg/kg
every 6 to 8hours produced levels from 8 to 12mcg/mL
in a study by Benner et al. Only the vancomycin dosing
regimens with the frequency of every 6 hours was able
to produce trough concentrations greater than 10mcg/mL.
None of the dosing strategies in either trial were able to
reach concentrations greater than 15mcg/mL needed for
more complicated infections per the new recommendations.
Interestingly, the mean age for each study was 5 years old,
falling into the shortest half-life group for vancomycin.
In a newer study of 430 pediatric patients aged from
1 month to 18 years old, Eiland and colleagues found
that vancomycin dosing strategies of 70mg/kg/day and
85mg/kg/day were needed to produce target serum trough
concentrations of 10mcg/mL and 15mcg/mL, respectively
[8]. Using the standard pediatric dosing regimens of 40
to 60mg/kg/day only reached therapeutic levels 49 percent
of the time based on the new higher serum trough con-
centration recommendations. The mean age of the patient
population was 5.9 years, which also fell into the child age
group.
In our study, those in the infant age group were more
likely to have a trough level in the 5 to 10mcg/mL range,4 International Journal of Pediatrics
while the patients in the child age group had more trough
concentrations less than 5mcg/mL. The adolescent group’s
trough concentrations were evenly divided between troughs
less than 5mcg/mL and 5 to 10mcg/mL. However, due to
the small sample size of adolescents, no conclusions can be
drawn though one would expect based on the hypothesized
adolescent half-life that their trough concentrations would
be similar to those of the infant group. We expect that
if our patient population had been larger, we might have
b e e na b l et os e em o r eo fat r e n dw i t he a c ha g eg r o u p .
Unfortunately, the sample size was small due to half of the
patients being excluded. Originally, we had set out to collect
and analyze more patient data, but due to the fact that all the
patients’ serum trough concentrations were subtherapeutic,
data collection was stopped early. Other limitations to the
study include its retrospective nature and the fact that it was
conducted at a single center.
Nonetheless, it is very important to provide a van-
comycin dosing regimen to patients that will lead to thera-
peutic concentration in a timely manner, since methicillin-
resistant Gram-positive pathogens, especially staphylococcus
aureus,h a v eb e c o m em o r ev i r u l e n ti nr e c e n ty e a r s .A sa
matter of fact, a study by Welsh and colleagues conﬁrmed
a high rate of vancomycin treatment failures (∼50%) in
pediatric patients with methicillin-resistant staphylococcus
aureus (MRSA) bacteremia [9]. This failure might have been
due to either subtherapeutic vancomycin trough concentra-
tions or the development of vancomycin-resistant MRSA.
The latter is of a grave concern, since there are limited
data on the use of other more powerful antimicrobials
treating methicillin-resistant or vancomycin-resistant Gram-
positivepathogensinthepediatricpopulation.Onepotential
alternative to vancomycin is linezolid. Numerous reports
and studies exist that describe the safe and eﬀective use
of linezolid in the pediatric population [10–12]; however,
there is not any comparative study between these two agents
(i.e., vancomycin and linezolid) in pediatric patients with
MRSA infections. If this study is to be conducted, the higher
vancomycin dosing strategies need to be considered in the
design in order to reach therapeutic concentration.
5. Conclusion
The traditional dosing schemes of vancomycin, including
our standard physician protocol of 15mg/kg every 8hours,
most likely do not produce therapeutic trough concen-
trations in otherwise healthy patients with normal renal
function. Our next step at the Moses H. Cone Memorial
Hospital is to start dosing vancomycin at 20mg/kg every
8hours for patients in the infant and adolescent age groups,
and vancomycin 15mg/kg every 6hours for patients in the
child age group. However, for our pediatric patients with
clinically signiﬁcant comorbidities (e.g., congenital heart
disease, nephrotic syndrome, and renal dysfunction), we
will continue dosing vancomycin at 15mg/kg every 8hours.
We then hope to evaluate these two dosing strategies in
the future, as these doses and/or frequencies may need to
be pushed even higher, especially for patients in the child
age group due to their short half-life. Large randomized
controlled trials are needed to determine the most appro-
priate dosing regimens of vancomycin in the pediatric
population, and the diﬀerences in pharmacokinetics must
be recognized in order to develop the best dosing for each
patient.
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